View in EDS

Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry: Insights from the Belgian Severe Asthma Registry

Saved in:
Bibliographic Details
Title: Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry: Insights from the Belgian Severe Asthma Registry
Authors: Demolder, Femke, Vanderhelst, Eef, Verbanck, Sylvia, Schleich, Florence, Louis, Renaud, Brusselle, Guy, Sohy, Carine, Michils, Alain, Peché, Rudi, Pilette, Charles, Hanon, Shane
Contributors: UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de pneumologie, Brussels Photonics, Pneumology, Physiotherapy, Human Physiology and Anatomy, Vitality Research Group, Clinical sciences
Source: Lung, Vol. 202, no. 4, p. 441-448 (2024)
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: Pulmonary and Respiratory Medicine, Male, Adult, Severe asthma, benralizumab, Anti-Asthmatic Agents/therapeutic use, Omalizumab/therapeutic use, Omalizumab, Biologics, Systèmes cardiovasculaire & respiratoire, Antibodies, Monoclonal, Humanized, Sciences de la santé humaine, Severity of Illness Index, Nasal Polyps, Belgium, Forced Expiratory Volume, Cardiovascular & respiratory systems, Humans, Registries, Anti-Asthmatic Agents, Human health sciences, Belgium/epidemiology, Asthma/physiopathology, Aged, Nasal polyposis, Asthma/drug therapy, Biological Products, Nasal Polyps/epidemiology, mepolizumab, Middle Aged, forced expiratory volume, Asthma, 3. Good health, Nasal Polyps/drug therapy, Nasal Polyps/complications, Treatment Outcome, Asthma/epidemiology, Female, Biological Products/therapeutic use, Super-response
Description: Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR).914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV1 in the NP + group. Super-response was achieved in 33 patients (32%), irrespective of NP status or type of biologic.In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV1 improvement as compared to SA patients without NP was observed.
Document Type: Article
Language: English
ISSN: 1432-1750
0341-2040
DOI: 10.1007/s00408-024-00715-0
Access URL: https://pubmed.ncbi.nlm.nih.gov/39007944
https://hdl.handle.net/2078.1/290094
https://biblio.vub.ac.be/vubir/(f78463a8-4043-40a6-9f0b-69c29f7b3f38).html
Rights: Springer Nature TDM
Accession Number: edsair.doi.dedup.....1c6facc0ef189ca44f25592a73e1c9af
Database: OpenAIRE
Description
Abstract:Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR).914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV1 in the NP + group. Super-response was achieved in 33 patients (32%), irrespective of NP status or type of biologic.In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV1 improvement as compared to SA patients without NP was observed.
ISSN:14321750
03412040
DOI:10.1007/s00408-024-00715-0